A Study to Determine Whether Necitumumab (IMC-11F8) Monotherapy Affects the Corrected QT (QTc) Interval in Patients With Advanced Solid Tumors
Phase of Trial: Phase II
Latest Information Update: 30 Sep 2016
At a glance
- Drugs Necitumumab (Primary)
- Indications Solid tumours
- Focus Pharmacodynamics
- Sponsors Eli Lilly
- 30 Sep 2016 Results of pooled analysis (N=807) of (I4X-IE-JFCA,JFCB,JFCC, JFCI,JFCJ) published in the Clinical Pharmacokinetics (2016).
- 30 Jul 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 16 Apr 2015 Planned End Date changed from 1 Apr 2015 to 1 Oct 2015, as reported by ClinicalTrials.gov.